Recent Anticoagulant Current Events | Anticoagulant News
|
|
|
Sort By:
Relevance | Page Views |
Designing drugs and their antidotes together improves patient care
Imagine a surgical patient on a blood-thinning drug who starts bleeding more than expected, and an antidote that works immediately - because the blood thinner and antidote were designed to work together. view more (2009-10-05)
New blood-thinning drug safer than rat poison
In an article reviewed by F1000 Medicine Faculty Members Robert Ruff, Brian Olshansky and Luis Ruilope, the blood-thinner dabigatran is shown to protect against stroke, blood clotting and major bleeding as effectively as warfarin, but with fewer side effects. view more (2009-09-30)
Drug-eluting stents better than bare-metal stents for heart attack patients
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the... view more... (2009-09-28)
Image-guided treatment for deep venous thrombosis could improve patients' long-term outcomes
Deep Venous Thrombosis (DVT) is a serious condition that involves the formation of a blood clot inside of a deep vein usually in the legs. A patient with DVT is typically treated with anticoagulants (blood thinners) however researchers have found that image-guided interventional radiology procedures may play a more central role in the long-term... view more... (2009-09-21)
Dabigatran vs. warfarin as long-term anticoagulant therapy in atrial fibrillation
The anticoagulant dabigatran is more effective than warfarin in the prevention of stroke in patients with atrial fibrillation, according to results from the RE-LY study (Randomized Evaluation of Long-term anticoagulant therapY). view more (2009-08-31)
'Artificial Golgi' may provide new insight into key cell structure
Scientists in New York and North Carolina are reporting assembly of the first functioning prototype of an artificial Golgi organelle. view more (2009-07-29)
The risk of developing deep vein thrombosis during a flight is often overestimated
The risk of developing deep vein thrombosis during a long flight is often overestimated. view more (2009-07-24)
New tool calculates risk of bleeding in heart attack patients
With eight basic medical facts in hand, doctors can now estimate the risk of bleeding for a patient having a heart attack. view more (2009-04-15)
Mutant rats resist warfarin
A new series of mutations have been discovered that allow rats to resist the effects of the popular poison warfarin. Research published in the open access journal BMC Genetics describes eighteen new genetic changes found in rats from four continents. view more (2009-02-06)
Arterial infusion using gabexate mesilate: Is it effective therapy for severe acute pancreatitis?
Severe acute pancreatitis (SAP) remains a lethal disease. It is defined as an inflammatory process of the pancreas with possible peripancreatic tissue and multi-organ involvement inducing multi-organ dysfunction syndrome (MODS) with an increased mortality rate. view more (2008-12-30)
Arterial infusion using gabexate mesilate: Is it effective therapy for severe acute pancreatitis?
Severe acute pancreatitis (SAP) remains a lethal disease. It is defined as an inflammatory process of the pancreas with possible peripancreatic tissue and multi-organ involvement inducing multi-organ dysfunction syndrome (MODS) with an increased mortality rate. view more (2008-12-29)
Research highlights new approaches to prevent blood clots
Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. view more (2008-12-08)
A reversal of thinking: How women with lupus can increase chance for healthy pregnancies
In the not so distant past, women with systemic lupus erythematosus (SLE), an autoimmune disease, were advised not to have children, and if they became pregnant, to have therapeutic abortions to prevent severe flares of their lupus. view more (2008-10-27)
DNA research taking guesswork out of finding the 'therapeutic window'
It's only spit, but what's inside your saliva may help solve a dosing dilemma facing doctors and patients. view more (2008-10-24)
HORIZONS AMI will help set guidelines for drug and stent therapy
The HORIZONS AMI clinical trial measuring the safety and efficacy of the use of the medication bivalirudin compared to standard drug therapy - heparin and glycoprotein IIb/IIIa inhibitors -- in heart attack patients who receive angioplasty, found that after 1 year, use of bivalirudin resulted in significantly lower rates of all-cause death, death... view more... (2008-10-16)
Women may stop anticoagulants after blood clots
Women may safely discontinue oral anticoagulants (blood thinners) after 6 months of treatment following a first unprovoked venous blood clot (thromboembolism) if they have no or one risk factor. view more (2008-08-26)
Computers as safe as medical experts for prescribing blood thinning drugs
The largest ever study into the administration of blood thinning drugs, principally Warfarin, has concluded that dosages calculated by computer are at least as safe and reliable as those provided by expert medical professionals. view more (2008-06-19)
Findings released from 1 of the largest percutaneous coronary intervention trials ever
A study led by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center/NewYork-Presbyterian and chairman of the Cardiovascular Research Foundation, has shown that heart attack patients who were administered the direct thrombin inhibitor bivalirudin during primary angioplasty had a reduced rate of adverse clinical events,... view more... (2008-05-27)
Landmark study reveals superiority of bivalirudin in heart attack patients at 30 days
The Cardiovascular Research Foundation (CRF) announced today that the New England Journal of Medicine published results of the HORIZONS AMI trial which showed the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduced net adverse clinical events by 24 percent compared to the standard treatment, as well as... view more... (2008-05-22)
Osteoporosis drug Fosamax linked to heart problem
omen who have used Fosamax are nearly twice as likely to develop the most common kind of chronically irregular heartbeat (atrial fibrillation) than are those who have never used it, according to research from Group Health and the University of Washington published in the April 28 Archives of Internal Medicine. view more (2008-04-29)
|
|
|
|
Sort By:
Relevance | Page Views |
|
